Prurigo clinical trials

The registry lists 38 studies for Prurigo across more than 10 countries. 10 are recruiting or about to start. 36 of them are mainly about Prurigo (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06.

Get an email when these change. Save the Prurigo studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 16
Recruiting: 7
Active, not recruiting: 5
Status unknown: 4
Not yet recruiting: 3
Terminated: 2

Phase

Phase 3: 17
Phase 2: 14
Phase 1: 3
Phase 4: 1

Where

United States: 23
Germany: 20
Poland: 16
France: 11
Canada: 11
Austria: 9

Who runs them

Incyte Corporation (6) · Galderma R&D (6) · Sanofi (3) · Trevi Therapeutics (3) · Celldex Therapeutics (2) · Shanghai Mabgeek Biotech.Co.Ltd (1) · Amgen (1) · Medical University of Graz (1)

What is being tested here

Drugs under test in Prurigo studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Lebrikizumab	1	0	1
Ruxolitinib	0	2	2
Nalbuphine	0	2	2
Nemolizumab	0	2	2
Dapsone Gel	0	0	1

Coming up

7phase 3 studies under way

4studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 4, phase 3 first

Oct 2027A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis · Phase 3 · Sanofi
Mar 2027Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis · Beijing InnoCare Pharma Tech Co., Ltd.
Aug 2027A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis. · Akeso
Nov 2027Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults · Galderma R&D

Who these studies take

Of the 7 Prurigo studies recruiting now, 4 (57%) set no upper age limit and 2 (29%) stop at 75 or younger. 2 (29%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 7
Age	Women	Men
10	2 (29%)	2 (29%)
18	6 (86%)	6 (86%)
30	6 (86%)	6 (86%)
40	6 (86%)	6 (86%)
50	6 (86%)	6 (86%)
65	6 (86%)	6 (86%)
75	6 (86%)	6 (86%)
85	4 (57%)	4 (57%)

Across all 38 studies, recruiting or not: 37% stop at 75 or younger and 8% at 65; 5% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 38 of 38. search them.